- Home
- MDGL vs FROG Comparison
MDGL vs FROG Comparison
Compare MDGL & FROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | FROG |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 10.5B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MDGL | FROG |
|---|---|---|
| Price | $545.73 | $81.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $674.45 | $65.75 |
| AVG Volume (30 Days) | 307.9K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.32 | 1.59 |
| EPS | N/A | ★ N/A |
| Revenue | $180,133,000.00 | ★ $531,840,000.00 |
| Revenue This Year | $58.39 | $20.37 |
| Revenue Next Year | $48.55 | $16.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.12 |
| 52 Week Low | $286.75 | $34.05 |
| 52 Week High | $615.00 | $99.22 |
Technical Indicators
Market Signals| Indicator | MDGL | FROG |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 42.22 |
| Support Level | $529.02 | $75.87 |
| Resistance Level | $545.29 | $89.16 |
| Average True Range (ATR) | 20.15 | 5.46 |
| MACD | -1.49 | -2.00 |
| Stochastic Oscillator | 30.54 | 6.88 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from united states and also has its presence in Israel, India and other regions.